



Points to Consider in Remote and Hybrid GMP/GDP Audits



Points to Consider in Remote and Hybrid GMP/GDP Audits Team

Authors

Auditing Subteam

Felicia Ford-Rice, Parexel International (Subteam Lead)
Robert L. Dana, Elkhorn Associates, Inc.
Gabriele Gori, GlaxoSmithKline
Alexander Nezlin, UroGen Pharma
Bryan Wilson, GlaxoSmithKline

Quality Risk Management Subteam

Tiffany Baker, ValSource, Inc. (Task Force Co-lead, Subteam Lead)
Felicia Ford-Rice, Parexel International
Ghada Haddad, PhD, Merck
Eva M. Urban, CSL Behring (Task Force Co-lead)

Culture and Communication Subteam

Karin Baer, NeuroDerm (Subteam Lead)
Vishal Sharma, Vi'enni Training & Consulting
Michele Simone, Bracco
Herbert Vail, PQE Group
Prashant Wange, Sun Pharmaceuticals

Technology Subteam

Raghu Ram Pannala, PhD, ScieGen Pharmaceuticals (Subteam Lead)
William Cashin, CordenPharma
Siegfried Schmitt, PhD, Parexel International
Herbert Vail, PQE Group

Task Force

Tiffany Baker, ValSource, Inc. (Co-lead)
Eva Urban, CSL Behring (Co-lead)
Karin Baer, NeuroDerm
William Cashin, CordenPharma
David Chesney, DL Chesney Consulting
Robert Dana, Elkhorn Associates
Alexandre Drapier, GlaxoSmithKline
Eser Earley, Astellas
Felicia Ford-Rice, Parexel International
Gabriele Gori, GlaxoSmithKline
Tor Gråberg, AstraZeneca

Ghada Haddad, PhD, Merck
Alexander Nezlin, UroGen Pharma
Raghu Ram Pannala, PhD, ScieGen Pharmaceuticals
Siegfried Schmitt, PhD, Parexel International
Vishal Sharma, Vi'enni Training and Consulting
Michele Simone, Bracco
Laura Singer, Heron Therapeutics
Prashant Wange, Sun Pharmaceutical Industries Ltd.
Herbert Vail, PQE Group
Bryan Wilson, GlaxoSmithKline

Points to Consider in Remote and Hybrid GMP/GDP Audits

ISBN: 978-1-945584-32-9

© 2022 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

Introduction	1	Topic A.1: Daily Wrap-Up and Audit Closing Meetings	20
Scope.....	1		
Glossary	2		
I. Determining Audit Type	4	VI. Reporting in a Remote or Hybrid Audit	22
Topic A.1: Using A Risk-Based Approach to Determine Audit Type	4	Topic A.1: Documenting the Nature of an Audit as Remote or Hybrid	22
II. Scheduling a Remote or Hybrid Audit	5	VII. Follow-up to a Remote or Hybrid Audit	23
Topic A.1: Scheduling.....	5	Topic A.1: Follow-Up.....	23
Topic A.2: Duration	6	VIII. References	24
III. Planning a Remote or Hybrid Audit	7	IX. Relevant Global Guidances	25
Topic A.1: Planning the Agenda for a Virtual or Hybrid Audit	7	X. Appendix I: Determining Audit Type Using a Risk-Based Approach	27
Topic B.1: Planning the Technology.....	8	Topic A.1 Audit Type: New Relationship Auditable Entity.....	27
Topic C.1: Planning for Document-Sharing	10	Topic A.2: Audit Type: Existing Relationship with Auditable Entity.....	31
Topic C.2: Preventing Communication Challenges During Document-Sharing	13	XI. Appendix II: Additional Considerations for Understanding the Role of Culture and Communication in Remote Audits	35
IV. Conducting a Remote or Hybrid Audit	15	Topic A.1: Use of Hofstede’s Power Distance Index to Create an Effective Verbal Communication Strategy for Remote Audit	35
Topic A.1: Opening Meetings	15		
Topic B.1: Communication	16		
V. Wrap-up and Closing of a Remote or Hybrid Audit	20		

FIGURES AND TABLES INDEX

Table 1 Options for Sharing Specific Types of Data in a Virtual Audit	12	Table AI.2-2 Historical Audit Performance Criteria and Risk-Ranking.....	32
Table 2 Example for Identifying Auditor’s Needs for Developing Document-Sharing Strategy for Remote Audits	14	Table AI.2-3 Auditable Entity Operational Performance Criteria	32
Table 3 Average Number of Words Spoken per Minute by Broadcasters.....	16	Table AI.2-4 Example Risk Assessment Worksheet for Auditable Entities with Existing Relationship.....	33
Table 4 Considerations for Nonverbal Communication in Virtual Audits.....	18	Figure AI.2-4 Risk Level Matrix.....	33
Figure AI.1-1 Filtering Decision Tree	27	Table AI.2-5 Action Level based on Overall Risk Score for Auditable Entity with Existing Relationship.....	34
Table AI.1-1 Criticality of Services Provided Criteria	28	Table AI.2-6 Action Level Ranking for Example of Auditable Entities with Existing Relationship.....	34
Table AI.1-2 Regulatory Compliance History Criteria and Risk Ranking	28	Table AII.1-1 Geography-Specific PDI Examples.....	36
Table AI.1-3 Example Risk Assessment Worksheet for New Auditable Entity.....	29	Table AII.1-2 Communication Strategy Suggestions based on PDI of the Auditee.....	37
Figure AI.1-2 Risk Level Matrix.....	29	Figure AII.1-1 Response to Question about Remote Interviews by Geography	38
Table AI.1-4 Action Level based on Risk Score.....	30	Table AII.1-3 Response to Question about Remote Interviews by Geography	38
Table AI.2-1 Risk-Ranking based on Criticality of Services Provided.....	31		
Figure AI.2-3 Preliminary Risk Level Matrix	32		

Table AII.1-4 Response to Question about Live Video Feed by Geography 39

Figure AII.1-1 Response to Question about Remote Interviews by Geography 39

Figure AII.1-3 Response to Question about Recording Proceedings by Geography..... 40

Table AII.1-5 Response to Question about Recording Proceedings by Geography..... 40

Table AII.1-6 Responses to Question about FDA Voluntary Regulatory Assessment by Geography 41

Figure AII.1-4 Response to Question about FDA Voluntary Regulatory Assessment by Geography 41



Bethesda Towers
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org